AHK-Cu — L-alanyl-L-histidyl-L-lysine copper(II), often labelled copper tripeptide-3 — is a synthetic copper-binding tripeptide researched almost exclusively for its interaction with the hair follicle. It is marketed alongside the better-known GHK-Cu as a "hair-specific" copper peptide, and the phrase "clinically proven" is attached to it with some regularity. This explainer sets out what the primary literature actually contains, what it does not, and how the compound sits under UK law.

What AHK-Cu is

AHK-Cu is a three-amino-acid chain — alanine, histidine, lysine — complexed with a copper(II) ion. It is a synthetic analogue of GHK-Cu (glycyl-L-histidyl-L-lysine copper), the naturally occurring plasma tripeptide first described by Loren Pickart in 1973, which has accumulated a far larger literature across skin, wound healing and gene-expression research [2]. The single alanine-for-glycine substitution at the N-terminus is the structural difference on which the "hair-specific" positioning rests: in the laboratory work that follows, AHK-Cu was investigated directly on human hair follicles and on dermal papilla cells (DPCs), the specialised fibroblasts at the base of the follicle that help regulate the hair growth cycle.

It is worth being precise from the outset. "Studied directly on human hair follicles" describes tissue in culture, not people. That distinction is the whole story of this compound's evidence base.

The primary evidence: a single 2007 laboratory study

The reference point for essentially all AHK-Cu claims is Pyo and colleagues' 2007 paper in Archives of Pharmacal Research [1]. Using human hair follicles maintained ex vivo (organ culture) and cultured human dermal papilla cells in vitro, the authors reported:

  • Follicle elongation ex vivo. AHK-Cu at concentrations between 10^-12 and 10^-9 M stimulated elongation of cultured human hair follicles.
  • DPC proliferation in vitro. The same concentration range increased proliferation of cultured dermal papilla cells.
  • Anti-apoptotic signalling. At 10^-9 M, the Bcl-2/Bax ratio was elevated and the cleaved forms of caspase-3 and PARP were reduced, consistent with a shift away from programmed cell death.

The paper's own conclusion — that AHK-Cu promotes human hair follicle growth, plausibly through DPC proliferation and reduced apoptosis — is a hypothesis drawn from laboratory tissue, and it is framed that way.

The finding that is usually left out

The same abstract reports that 10^-9 M AHK-Cu "reduced the number of apoptotic DPCs, but this decrease was not statistically significant" [1]. The apoptotic-cell-count reduction did not reach significance; the supportive evidence is the downstream marker profile (Bcl-2/Bax, caspase-3 and PARP), not the primary apoptosis count. Secondary write-ups that describe a clean anti-apoptotic effect typically omit that caveat. It matters, because it is the difference between a single statistically significant observation and a suggestive one.

What the study cannot show

A laboratory study of this type establishes mechanism and plausibility; it cannot establish efficacy in people. Specifically [1][3]:

  • No clinical trial exists. There is no published randomised controlled trial of AHK-Cu in humans for hair loss. The human evidence base remains preclinical — tissue in culture rather than application to a scalp — and recent reviews of short peptides in hair loss classify AHK-Cu's support as experimental.
  • The tissue was not the target tissue. The follicles studied were taken from the occipital scalp, the region least affected by androgenetic alopecia. Follicles from the frontal and vertex scalp, where pattern hair loss typically appears, may respond differently.
  • The donor base was small. Although a large number of follicles were used, they came from a very small number of volunteers, so individual variation is not well represented.
  • Concentration is not delivery. The 10^-9 M range describes the concentration in the culture medium bathing the tissue. It says nothing about how much peptide reaches the dermal papilla when a topical product is applied to intact scalp, across skin, sebum and the follicular barrier.

Common figures, and what they actually mean

Popular summaries circulate two numbers: that AHK-Cu increases hair follicle size by roughly 40%, and that it increases follicle proliferation by around 50%. These derive from in-vitro and ex-vivo measurements — fold-changes in cultured cells or cultured follicles over short exposure windows — not from hair counts or photographic assessments in people. They are laboratory effect sizes, and they should not be read as expected outcomes in human use. Peptide Data's evidence grading treats a compound's human-data ceiling as the binding constraint, and on that basis AHK-Cu sits at Limited/anecdotal: real mechanistic plausibility, an extremely thin human record.

UK regulatory status

AHK-Cu holds no marketing authorisation from the MHRA or the EMA, and it is not a licensed medicine in the UK or the EU [4]. It is supplied as a research chemical and, in topical formulations, as a cosmetic ingredient.

This creates a boundary that vendors routinely blur. Under the Human Medicines Regulations 2012, a product presented for the treatment or prevention of disease — including hair loss framed as a condition to be treated — may be a medicinal product requiring a licence, whatever it is called [4]. Products sold purely as cosmetics, with appearance-based claims, sit under a different regime; products sold with medicinal claims do not. For research peptides, the "research use only" framing is the only defensible one, and it rules out human consumption, dosing or self-administration guidance of any kind.

Any statement that AHK-Cu "treats hair loss", or is "clinically proven" to regrow hair, is not supported by the literature and would constitute a medicinal claim.

How to read the evidence

AHK-Cu is a legitimate object of laboratory research with a plausible, if incompletely characterised, mechanism in follicular biology. It is not a compound with a human evidence base. The honest summary is: one 2007 study, in cultured human tissue, showing elongation and proliferation at laboratory concentrations, with a statistically non-significant apoptosis count and an otherwise supportive signalling profile; no clinical trials; no UK licence; research-use only. Treat marketing that says otherwise as marketing.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.